Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.
In the dexamethasone-treated rat model of cryptosporidiosis, paromomycin was effective at a dosage of 50 mg/kg/day or more for ileal infection and 200 mg/kg/day or more for cecal infection. At 1 and 3 weeks after treatment, a persistent infection was demonstrated in all rats. These results confirm the anticryptosporidial activity of paromomycin and underscore the limitations of this compound because of its potential toxicity at such high dosages and its inability to eradicate the infection.
Institut National de la Santé et de la Recherche Médicale, Unité 13, Hôpital Bichat-Claude-Bernard, Paris, France.
R
R
Verdon
J
J
Polianski
C
C
Gaudebout
C
C
Marche
L
L
Garry
C
C
Carbon
J J
JJ
Pocidalo
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003457:Cryptosporidiosis / Q000188:drug therapy* / Q000469:parasitology; D016785:Cryptosporidium parvum; D003907:Dexamethasone / Q000494:pharmacology*; D005243:Feces / Q000382:microbiology; D005260:Female; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010303:Paromomycin / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D010303:Paromomycin; D003907:Dexamethasone